Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of melphalan, prednisone, thalidomide and bortezomib in advanced refractory multiple myeloma
2004-000565-34Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan, prednisone, thalidomide and bortezomib in multiple myeloma (MM), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Response rate per EBMT criteria. Started Oct 2007; status: active.
02
Drugs
melphalanprednisonethalidomidebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2004-000565-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000565-34.